Kiora Pharmaceuticals (KPRX) Invested Capital (2016 - 2025)
Kiora Pharmaceuticals (KPRX) has disclosed Invested Capital for 11 consecutive years, with $22.4 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Invested Capital fell 25.37% year-over-year to $22.4 million, compared with a TTM value of $22.4 million through Sep 2025, down 25.37%, and an annual FY2024 reading of $25.8 million, up 321.62% over the prior year.
- Invested Capital was $22.4 million for Q3 2025 at Kiora Pharmaceuticals, up from $22.1 million in the prior quarter.
- Across five years, Invested Capital topped out at $34.9 million in Q1 2024 and bottomed at $6.1 million in Q4 2023.
- Average Invested Capital over 5 years is $18.0 million, with a median of $15.3 million recorded in 2021.
- The sharpest move saw Invested Capital tumbled 37.54% in 2022, then soared 321.62% in 2024.
- Year by year, Invested Capital stood at $14.6 million in 2021, then dropped by 25.68% to $10.8 million in 2022, then tumbled by 43.61% to $6.1 million in 2023, then skyrocketed by 321.62% to $25.8 million in 2024, then fell by 13.0% to $22.4 million in 2025.
- Business Quant data shows Invested Capital for KPRX at $22.4 million in Q3 2025, $22.1 million in Q2 2025, and $23.7 million in Q1 2025.